Agilus Diagnostics Launches Advanced Laboratory in Himachal Pradesh
Wednesday, September 13, 2023
Agilus Diagnostics, a subsidiary of Fortis Healthcare Limited., today announced the launch of a new laboratory in Tanda, Himachal Pradesh. The advanced laboratory has the capacity to process 30,000+ samples in a month ranging from simple routine tests to semi-specialized and specialized tests. Recognizing the rising demand for quality diagnostic services, Agilus has expanded its capabilities by launching this laboratory in Tanda. The citizens of Tanda will now have access to Agilus’ extensive test menu comprising of 3,000+ tests and a range of well-curated preventive healthcare packages. This new Agilus lab in Tanda along with its existing lab in Shimla will also cater to Kangra, Palampur and Dharmashala.
Mr. Anand K, Managing Director & CEO, Agilus Diagnostics said ‘Agilus Diagnostics had been catering to the populace in Himachal Pradesh for over a decade through a PPP project with the state government. Now, we are excited to expand our services through our own laboratory facilities. We have also enabled home collection services for the benefit of our customers and other valued added services like ordering tests through our website and intuitive mobile app, receiving diagnostic reports through WhatsApp etc. In addition, we believe that our expansive test menu will help the local citizens and doctors to access a large number of tests.”
The advanced laboratory spread over 3000 Sqft has multiple laboratory divisions including Hematology, Biochemistry, Clinical Pathology, Serology and Microbiology. The laboratory is located at: Agilus Diagnostics, Main Tanda market , Opposite Tanda Medical College Tanda , Kangra , 176001. Customers can easily book tests by calling 91115 91115 or through the Agilus website or mobile app or can contact the lab by calling 01892293283.
Agilus Diagnostics endeavours to be the laboratory of choice for patients, doctors and hospitals across its network.
About Agilus Diagnostics
(A subsidiary of Fortis Healthcare Ltd.)
Instituted in 1995, Agilus Diagnostics Ltd., is one of India’s largest diagnostics service provider in terms of number of laboratories in India as of and for the financial year ended March 31, 2023 (Source: CRISIL Report). Agilus Diagnostics has a network of 410+ labs, 3700+ customer touch points, and 12000+ direct clients/pick up points spread across 1000+ cities, 25 states and five union territories in India as of March 31, 2023. The company has recently undergone a brand transformation journey and has adopted a new name Agilus Diagnostics. Agilus is a portmanteau of ‘Agile’ and ‘Us’ and is inspired from the Latin term ‘agilis’ which means ‘agility’. Agilus offers more than 3,000 tests and test combinations, ranging from routine tests to esoteric and genetic tests. The company has the largest number of NABL accredited labs in the country as of March 31, 2023 (Source: CRISIL Report) with 43 NABL accredited labs, 3 NABL M(EL)T certified labs and 2 CAP accredited labs. Its international network consists of centers across the SAARC region, Sub-Saharan Africa, South-East Asia and the Middle East. Agilus is committed to research and development and focused on genomics and ‘next-generation diagnostics’ and delivering a customer-centric experience through an integrated and seamless technology platforms and data-driven actionable insights.
Disclaimer: Agilus Diagnostics Limited (formerly SRL Limited) having its registered office at Fortis Hospital, Sector 62, Phase – VIII Mohali – 160062 (Punjab), www.agilusdiagnostics.com, CIN U74899PB1995PLC045956, is proposing, subject to receipt of requisite approvals, market conditions and other considerations, an initial public offer of its equity shares in the near future and is in the process of filing a draft red herring prospectus with the Securities and Exchange Board of India. The equity shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. The equity shares may only be offered and sold (a) in the United States only to “qualified institutional buyers” (as defined in Rule 144A), in private transactions exempt from the registration requirements of the U.S. Securities Act, and (b) outside of the United States in offshore transactions as defined in and in compliance with Regulation S and the applicable laws of the jurisdiction where any such offers and sales are made. There will be no public offering in the United States.
For more information
Nadhiya Mali
Head, PR & Corporate Communications
Agilus Diagnostics Ltd.
8879009517 / nadhiya.mali@agilus.in
Source: agilus.in